Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.47 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | CCR8 | P51685 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7027271 | 0.87 | CCR1 (0.44) | IRAK4CCR1CCR8NOS3NOS2 | |
| SCHEMBL522953 | 0.86 | ALDH1A1 (0.44) | IRAK4NOS2CXCR4ALDH1A1TSHR | |
| SCHEMBL5024861 | 0.84 | CCR1 (0.46) | IRAK4CCR1CCR8NOS3NOS2 | |
| SCHEMBL25513930 | 0.83 | CCR1 (0.41) | IRAK4CCR1CCR8NOS3NOS2 | |
| SCHEMBL12088608 | 0.80 | CXCR4 (0.42) | IRAK4CCR1CCR8NOS3NOS2 | |
| SCHEMBL12660023 | 0.79 | CCR1 (0.41) | CCR1CCR8NOS3NOS2RAB9A | |
| SCHEMBL19364109 | 0.79 | GRIN2D (0.44) | IRAK4CCR1CCR8NOS3NOS2 | |
| SCHEMBL14821397 | 0.79 | CXCR4 (0.44) | CCR1CCR8NOS3NOS2RAB9A | |
| SCHEMBL10272748 | 0.78 | GRIN2D (0.42) | IRAK4CXCR4ALDH1A1TSHR | |
| SCHEMBL23425851 | 0.78 | MBOAT4 (0.39) | IRAK4ALDH1A1TSHRMBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025053198-A1 | HALF-DRY SMELL COMPOSITION AND MASKING FRAGRANCE COMPOSITION | 高砂香料工業株式会社 | 2025-03-13 | — | — | WO | disclosed |
| WO-2024107393-A1 | TRICYCLIC COMPOUNDS | SCHRÖDINGER, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2021050964-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2021-03-18 | — | — | WO | disclosed |
| WO-2019074979-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | GIRAFPHARMA, LLC (US) | 2019-04-18 | — | — | WO | disclosed |
| EP-1957498-B1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC (CA) | 2017-02-15 | — | — | EP | disclosed |
| EP-2301930-B1 | Derivatives of hexahydrobenzofuranone useful for the treatment of (inter alia) auto-immune or inflammatory disorders | MERCK SHARP & DOHME (US) | 2016-01-06 | — | — | EP | disclosed |
| US-8183275-B2 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183275-B2 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-22 | — | — | US | disclosed |
| EP-2301930-A1 | Thrombin receptor antagonists | Schering Corporation (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| WO-2008051405-A1 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| EP-1294714-B1 | THROMBIN RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1764366-A2 | Thrombin receptor antagonists | SCHERING CORPORATION (US) | 2007-03-21 | — | — | EP | disclosed |
| EP-0000106-B1 | 2-ALKYL NICOTINOIDS AND PROCESSES FOR THEIR PRODUCTION AND USE | PHILIP MORRIS INCORPORATED (US) | 1982-02-17 | — | — | EP | disclosed |
| US-4220781-A | QUARTINIZATION, REARRANGEMENT AND REDUCTION | PHILIP MORRIS, INC. (US) | 1980-09-02 | — | — | US | disclosed |
| US-4155909-A | INSECTICIDES | PHILIP MORRIS INCORPORATED (US) | 1979-05-22 | — | — | US | disclosed |
| EP-0000106-A1 | 2-Alkyl nicotinoids and processes for their production and use | PHILIP MORRIS INCORPORATED (US) | 1978-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | BRS3, GPR119, GIPR | IRAK4 1872/4885CCR1 3313/4885CCR8 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.